Share Your Listing on Social Media to Increase Visibility

Report Abuse

Bacteriophage_Market_Report_2035_RootsAnalysis
$5,899.00
0 0 Reviews
Popular

Bacteriophage therapeutics market Trends, Analysis by 2035

Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.

 

Key Market Insights

  • Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases
  • Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration
  • Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide
  • Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players
  • A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain
  • Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics
  • Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017
  • The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions
  • Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics
  • The market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions

 

Table of Content

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Market Segmentations

1.3.                  Research Methodology

1.4.                  Key Questions Answered

1.5.                  Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                  Chapter Overview

3.2.                  Historical Evolution of Bacteriophages

3.3.                  Biology of Bacteriophages

3.4.                  Introduction to Bacteriophage Therapy

3.5.                  Applications of Bacteriophage Therapy

3.6.                  Advantages of Bacteriophage Therapy

3.7.                  Limitations of Bacteriophage Therapy

3.8.                  Conclusion

 

  1. BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Bacteriophage Therapeutics: Drug Pipeline

4.2.1.               Analysis by Phase of Development

4.2.2.               Analysis by Therapeutic Area

4.2.3.               Analysis by Phase of Development and Therapeutic Area

4.2.4.               Analysis by Targeted Bacterial Strain

4.2.5.               Analysis by Target Disease Indication

4.2.6.               Analysis by Type of Therapy

4.2.7.               Analysis by Route of Administration

 

4.3.                  Information on Bacteriophage Related Technologies

 

  1. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE

5.1.                  Chapter Overview

5.2.                  Bacteriophage Therapeutics: List of Developers

5.2.1.               Analysis by Year of Establishment

5.2.2.               Analysis by Company Size

5.2.3.               Analysis by Location of Headquarters

5.2.4.               Analysis by Company Size and Location of Headquarters

5.2.5.               Leading Developers: Analysis by Number of Bacteriophage Therapeutics

 

  1. COMPANY AND DRUG PROFILES

6.1.                  Chapter Overview

6.2.                  Eliava BioPreparations

6.2.1.               Company Overview

6.2.2.               Financial Information

6.2.3.               Pipeline Overview

6.2.3.1.                        Pyo Bacteriophage

6.2.3.2.                        Intesti Bacteriophage

6.2.3.3.                        SES Bacteriophage

6.2.3.4.                        Staphylococcal Bacteriophage

6.2.3.5.                        Fersisi Bacteriophage

6.2.3.6.                        Enko Bacteriophage

6.2.4.               Recent Developments and Future Outlook

 

6.3.                  Micreos

6.3.1.               Company Overview

6.3.2.               Financial Information

6.3.3.               Pipeline Overview

6.3.3.1.                        PhageGuard Listex

6.3.3.2.                        PhageGuard S

6.3.3.3.                        PhageGuard E

6.3.4.               Recent Developments and Future Outlook

 

6.4.                  NPO Microgen

6.4.1.               Company Overview

6.4.2.               Financial Information

6.4.3.               Pipeline Overview

6.4.3.1.                        E. coli-Proteus Bacteriophage

6.4.3.2.                        Streptococcus Bacteriophage

6.4.3.3.                        Complex Pyobacteriophage

6.4.3.4.                        Klebsiella Purified Polyvalent Bacteriophage

6.4.3.5.                        Sextaphag

6.4.3.6.                        Dysentery Bacteriophage

6.4.3.7.                        Intesti

6.4.4.               Recent Developments and Future Outlook

 

6.5.                  ContraFect

6.5.1.               Company Overview

6.5.2.               Financial Information

6.5.3.               Pipeline Overview

6.5.3.1.                        Exebacase (CF-301)

6.5.3.2.                        CF-296

6.5.3.3.                        CF-370

6.5.3.4.                        Gram-Negative Lysins

6.5.3.5.                        Amurins

6.5.4.               Recent Developments and Future Outlook

 

6.6.                  Adaptive Phage Therapeutics

6.6.1.               Company Overview

6.6.2.               Financial Information

6.6.3.               Pipeline Overview

6.6.3.1.                        Bacteriophage Therapeutics

6.6.4.               Recent Developments and Future Outlook

 

6.7.                  Phagelux

6.7.1.               Company Overview

6.7.2.               Financial Information

6.7.3.               Pipeline Overview

6.7.3.1.                        PGX-0100

6.7.3.2.                        BactelideTM

6.7.3.3.                        BactelideTM

6.7.4.               Recent Developments and Future Outlook

 

6.8.                  Pherecydes Pharma

6.8.1.               Company Overview

6.8.2.               Financial Information

6.8.3.               Pipeline Overview

6.8.3.1.                        Bacteriophage Therapeutics

6.8.4.               Recent Developments and Future Outlook

 

  1. CLINICAL TRIAL ANALYSIS

7.1.                  Chapter Overview

7.2.                  Scope and Methodology

 

7.3.                  Bacteriophage Therapeutics Market: Clinical Trial Analysis

7.3.1.               Analysis by Trial Registration Year

7.3.2.               Analysis by Trial Registration Year and Enrolled Patient Population

7.3.3.               Analysis by Trial Status

7.3.4.               Analysis by Trial Phase and Enrolled Patient Population

7.3.5.               Analysis by Study Design

7.3.6.               Analysis by Type of Sponsor / Collaborator

7.3.7.               Most Active Players: Analysis by Number of Registered Trials

 

7.3.8.               Regional Analysis

7.3.8.1.                        Analysis by Number of Registered Trials

7.3.8.2.                        Analysis by Enrolled Patient Population

 

  1. PATENT ANALYSIS

8.1.                  Chapter Overview

8.2.                  Scope and Methodology

 

8.3.                  Bacteriophage Therapeutics: Patent Analysis

8.3.1.               Analysis by Publication Year

8.3.2.               Analysis by Patent Application Year

8.3.3.               Analysis by Annual Number of Granted Patent(s) and Patent Application(s)

8.3.4.               Analysis by Geography

8.3.5.               Analysis by CPC Symbols

8.3.6.               Analysis by Type of Applicant

8.3.7.               Leading Players: Analysis by Number of Patents

 

8.4.                  Bacteriophage Therapeutics: Patent Benchmarking

8.4.1.               Analysis by Patent Characteristics

 

8.5.                  Bacteriophage Therapeutics: Patent Valuation

8.6.                  List of Leading Patents

 

  1. PUBLICATION BENCHMARKING ANALYSIS

9.1.                  Chapter Overview

9.2.                  Scope and Methodology

 

9.2.1.               Analysis by Year of Publication

9.2.2.               Analysis by Type of Article

9.2.3.               Analysis by Popular Keywords

9.2.4.               Popular Publishers: Analysis by Number of Publications

9.2.5.               Popular Journals: Analysis by Number of Publications

9.2.6.               Popular Journals: Analysis by Journal Impact Factor

9.2.7.               Publications: Timeline Analysi

9.3.                  Publication Benchmarking

 

  1. ACADEMIC GRANTS ANALYSIS

10.1.                Chapter Overview

10.2.                Scope and Methodology

 

10.3.                Bacteriophage Therapeutics: Academic Grant Analysis

10.3.1.             Analysis by Year of Grant Award

10.3.2.             Analysis by Amount Awarded

10.3.3.             Analysis by Administering Institute Center

10.3.4.             Analysis by Support Period

10.3.5.             Analysis by Funding Institute Center and Support Period

10.3.6.             Analysis by Type of Grant Application

10.3.7.             Analysis by Purpose of Grant Award

10.3.8.             Analysis by Activity Code

10.3.9.             Word Cloud Analysis: Emerging Focus Areas

10.3.10.           Analysis by Study Section Involved

10.3.11.           Popular NIH Departments: Analysis by Number of Grants

10.3.12.           Analysis by Type of Recipient Organization

10.3.13.           Prominent Program Officers: Analysis by Number of Grants

10.3.14.           Popular Recipient Organizations: Analysis by Number of Grants

10.3.15.           Regional Distribution of Recipient Organizations

 

  1. FUNDING AND INVESTMENT ANALYSIS

11.1.                Chapter Overview

11.2.                Types of Funding

11.3.                Bacteriophage Therapeutics Market: List of Funding and Investments

11.3.1.             Analysis by Year of Investment

11.3.2.             Analysis by Amount Invested

11.3.3.             Analysis by Type of Funding

11.3.4.             Most Active Players: Analysis by Number of Funding Rounds and Amount Raised

11.3.5.             Investors Analysis

11.3.6.             Regional Distribution by Amount Invested

 

11.4.                Concluding Remarks

 

  1. PARTNERSHIPS AND COLLABORATIONS

12.1.                Chapter Overview

12.2.                Partnership Models

12.3.                Bacteriophage Therapeutics: List of Partnerships and Collaborations

12.3.1.             Analysis by Year of Partnership

12.3.2.             Analysis by Type of Partnership

12.3.3.             Analysis by Year of Partnership and Type of Partner

12.3.4.             Analysis by Therapeutic Area

12.3.5.             Analysis by Application Area

12.3.6.             Most Active Players: Analysis by Number of Partnerships

 

12.3.7.             Regional Analysis

12.3.7.1.          Intercontinental and Intracontinental Agreements

 

  1. START-UP HEALTH INDEXING

13.1.                Chapter Overview

13.2.                Bacteriophage Therapeutics Developers: Start-ups

13.2.1.             Analysis by Location of Headquarters

 

13.3.                Benchmarking of Start-ups

13.3.1.             Analysis by Pipeline Strength

13.3.2.             Analysis by Pipeline Maturity

13.3.3.             Analysis by Indication Diversity

13.3.4.             Analysis by Number of Patents

13.3.5.             Analysis by Funding Amount

13.3.6.             Analysis by Partnership Activity

13.3.7.             Start-ups Health Indexing: Roots Analysis Perspective

 

  1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14.1.                Chapter Overview

14.2.                Scope and Assumptions

14.3.                Forecast Methodology

 

14.4.                Global Bacteriophage Therapeutics Market, 2022-2035

14.4. 1.                        Bacteriophage Therapeutics Market, 2022-2035: Distribution by Therapeutic Area

14.4.1.1.          Bacteriophage Therapeutics Market for Gastrointestinal Infectious, 2022-2035

14.4.1.2.          Bacteriophage Therapeutics Market for Bacterial Dysentery, 2022-2035

14.4.1.3.          Bacteriophage Therapeutics Market for Multiple Infections, 2022-2035

 

14.4. 2.                        Bacteriophage Therapeutics Market, 2022-2035: Distribution by Route of Administration

14.5.2.1.          Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035

14.5.2.2.          Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035

14.5.2.3.          Bacteriophage Therapeutics Market for Intravesical Therapies, 2022-2035

14.5.2.4.          Bacteriophage Therapeutics Market for Topical Therapies, 2022-2035

 

14.4. 3.                        Bacteriophage Therapeutics Market, 2022-2035: Distribution by Geography

14.6.3.1.          Bacteriophage Therapeutics in North America, 2022-2035

14.6.3.2.          Bacteriophage Therapeutics in Europe, 2022-2035

 

  1. CONCLUSION

 

  1. EXECUTIVE INSIGHTS

16.1.                Chapter Overview

16.2.                Rime Bioinformatics

16.2.1.             Company Snapshot

16.2.2.             Interview Transcript: Antoine Culot, Chief Executive Officer

 

16.3.                BiomX

16.3.1.             Company Snapshot

16.3.2.             Interview Transcript: Iddo Weiner, Senior Director, Head of Data-Science

 

16.4.                Hospices Civils De Lyon

16.4.1.             Organization Snapshot

16.4.2.             Interview Transcript: Mathieu Medina, Project Leader

 

16.5.                Independent Consultant

16.5.1.             Interview Transcript: Mohammadreza Azizkhani, Scientific Researcher

 

  1. APPENDIX I: TABULATED DATA

 

  1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

 

For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html

 

You may also be interested in the following titles:

Lab Automation Market
Cannabis Testing Market

 

You may also like to learn what our experts are sharing in Roots educational series:

T-cell Immunotherapies: The Future of Modern Cancer Treatments
Monkeypox: Disease Overview, Transmission and Diagnosis

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

 

 

Location

Author Info

berrycristan

Member since 11 months ago
  • berrycristanm01992@gmail.com
View Profile

Contact Listings Owner Form

Bacteriophage therapeutics market Trends, Analysis by 2035 0 reviews

Login to Write Your Review

There are no reviews yet.